*1 advice, bringing subpoena other than attorney. ZAK, Individually
to the There no evidence Roman and On comparison subpoena of a of the Similarly Behalf of All Others and earlier issue different search war- Situated, Plaintiff-Appellant, rant. And there was no testi- likewise and
mony attorney, from the and no indica- previous testimony tion McIntyre, Individually Cameron and
defendant, that relying upon she was Similarly On Behalf of All Others ... for advice of counsel her reasons for grand jury. Situated, Plaintiff, her conduct before the predicate Court finds that the first counsel, the advice of full disclosure of facts, pertinent all has not been estab- CHELSEA INTER- THERAPEUTICS lished. And so the Court will find that NATIONAL, LTD.; Pedder; Simon the advice of counsel defense is not war- Schwieterman, William D. Defen- ranted this case. dants-Appellees, sum,
J.A. 365. the court found West- brooks’s evidence insufficient to establish a and prima facie defense. advice-of-counsel
Clearly a court must be able to consider a Hewitt; L. Arthur J. Nick reliability defendant’s strength and the Riehle, Defendants. determining her evidence in whether she No. 13-2370.
has production regard- met her burden of an ing аffirmative defense. evalua- Such United States Court of Appeals, tion does not shift the ultimate burden of Fourth Circuit. Here, proof. analyzed the district court testimony, including Westbrooks’s her Argued: Dec. statement that she did not disclose to her lawyer the 10% of paper records the IRS Decided: March left behind when it executed the search
warrant, J.A. concluded
Westbrooks “full failed to establish disclo- all pertinent
sure of facts.” It then found government had “established the beyond
elements of criminal contempt
reasonable doubt.” J.A. 365. The court impermissibly
did not shift the burden of
proving willfulness to Westbrooks.
IV. reasons,
For foregoing we affirm
Westbrooks’s conviction.
AFFIRMED. *3 Whitman, Wy- Hampson, S.
Lee M. Tobias LLP, Ra- Yates & Ponton rick Robbins Carolina; Watts, L. Gregory leigh, North Salceda, Seattle, E. Washington, Ignacio Sonsini Goodrich Cheryl Foung, W. Wilson Alto, California, Rosati, Appel- Palo & International, Therapeutics lees Chelsea Pedder, Ltd., D. and William Simon Schwieterman. and, TRAXLER, Judge,
Before Chief THACKER, Circuit KEENAN Judges. *4 by published and remanded
Vacated Judge KEENAN wrote the opinion. TRAXLER Judge in which Chief opinion, a joined. Judge THACKER wrote dissenting opinion. separate KEENAN, BARBARA MILANO Judge: Circuit that plaintiffs in this case claim International, LTD. Therapeutics Chelsea (Chelsea) corporate and several of its offi- defendants) (collectively, the violated cers 10(b) Exchange of the Securities Section (the Act), 15 Exchange Act оf 1934 U.S.C. Roman 78j(b).2 § Chelsea stockholder Zak, individually repre- both and as class (the plain- for other investors sentative tiffs), the defendants made alleged materially misleading statements and development and like- omissions about regulatory approval for a new lihood of Gonnello, considering the de- drug, Northera. After Richard William ARGUED: LLP, York, filed under New fendants’ motion dismiss Faruqi Faruqi, & New 12(b)(6), Rule of Procedure York, Barry Kaplan, M. Federal Civil Appellant. for Rosati, Seattle, complaint, the district court dismissed Goodrich & Wilson Sonsini plaintiffs’ allegations were holding BRIEF: Washington, Appellees. ON However, Riehle are not Dr. Hewitt and Mr. named as individual defen- 1. The Pedder, appeal. parties to this and Chief dants Dr. Simon President Officer; Schwieter- Executive Dr. William man, claim, and Chief Medical Offi- plaintiffs Vice President also al- a derivative In cer; Hewitt, leged Vice President and violated Dr. Arthur the individual defendants Act, Officer; Riehle, 20(a) Exchange 15 U.S.C. and Mr. Nick Section Chief Scientific 78t(a). Officer. Vice President and Chief Financial Ltd., 308, 322, establish as matter of law to 551 U.S. insufficient S.Ct. (2007)). the re- the defendants acted with L.Ed.2d 179 be- quired sciеnter. gan gain its approval effort from the (FDA) Drug Food and Administration con- appeal, contend On right cerning to market court errors. the district committed two Northera3 as treatment for symptomatic (1) errors are: the court’s The asserted (NOH). neurogenic hypotension orthostatic of certain documents filed consideration NOH is a condition which a dramatic Exchange with the Securities and Commis- drop pressure per- blood occurs when a (SEC) that exhibits sion were submitted as drop son stands. This pressure blood dismiss; with the defendants’ motion to dizziness, symptoms causes such im- (2) the court’s determination that the vision, weakness, nausea, paired fatigue, were plaintiffs’ allegations of scienter le- inability clearly. and an to think NOH is gally insufficient. presence associated with of various review, our Upon we hold that dis- including disease, disorders Parkinson’s judicial erred in notice of taking trict court multiple systems atrophy, and auto- pure challenged documents with the filed nomic failure. SEC, those documents did not because complaint. the contents of relate to considering “significant After unmet further hold that this error was not We clinically need” for a beneficial treatment harmless, incorrectly because the court NOH, symptomatic assigned the FDA *5 supporting these construed documents as “orphan drug Northera status.” Such sta- holding plaintiffs’ allegations that the of its provided years tus Chelsea with seven of legally Finally, scienter were insufficient. exclusivity, marketing and reduced certain we on hold based the defendants’ requirements time expense and related to to failure disclose critical information clinical trials mandated for FDA approval about the weaknesses of the new of drug. the plaintiffs’ the were application, submitting drug applica- Before its “new support to inference of sufficient FDA, tion” nu- Chelsea conducted We therefore district scienter. vacate the clinical merous trials with “end- certain judgment dismissing court’s the points,” goals, to demonstrate complaint and remand the for further case efficacy drug’s safety. and As relevant to proceedings. Chelsea appeal, conducted four effica- 303, cy trials, namely, 301, 302, Studies
I. and 3064 alleged pleadings their facts, following accept which and in 2008. began Studies 301 302 our court’s Both had general true in review of the district those studies the same of efficacy demonstrating dismissal under Federal a statis- endpoint 12(b)(6). tically significant lightheadedness Rule of Civil Procedure Matrix effect on Fund, Mgmt. BearingPoint, LP and for individuals from Capital suffering dizziness Cir.2009) (cit- Inc., 172, endpoint .Study F.3d for 301 set NOH. The was Tellabs, ing Rights, “special protocol Inc. v. Makor & forth in a assessment” Issues drug’s droxidopa. directly are not our 3. The trade name is those trials relevant to appeal. analysis in this also conducted to es- Chelsea clinical trials drug’s safety, tablish but the results of longer agreement significantly an which included treat- (SPA), was between which 302, study periods FDA that the de- ment than 301 and did and the Studies Chelsea size, and clinical could sign, goals not meet and failed to endpoint, trial its demon- in- approval. The SPA support regulatory any drug provided strate that the “dura- also stated that Study 306, volving symptoms. Study tion effect” on efficacy two successful expected FDA significantly longer which included a alsо grant regulatory it would studies before abandoned an period, treatment was after drug. approval the new analysis study interim indicated endpoint.5 would not meet its conclude, study Study to first primary endpoint. its Later to meet failed 10, 2010, On December Chelsea met documents showed results FDA the viability with officials to assess “clearly efficacy ... dr[e]w the Study 302 submitting drug application a new based question,” drug] into and demon- [the (the Study on December 2010 meet- symptoms worsened for those strated that ing). meeting, the December 2010 During taking drug. individuals FDA warned that a again officials Chelsea announced to investors After Chelsea single study typically successful Study results from disappointing support approval sufficient to of a new FDA petitioned modify to Chelsea Nevertheless, drug. Chelsea announced Study 301, endpoint for which was SPA’s “agreed” FDA had Chelsea’s rep- In November ongoing. Chelsea drug application new for Northera could officials, resentatives met with Study on data from be submitted based later informed investors the FDA had only study primary to meet its agreed permit use a different Study endpoint, and data frоm which Study for assessment scale 301 than was primary endpoint, had not met its without The FDA Study used in officials also efficacy need further studies. had at the recommended November 2009 meeting that Chelsea submit “a confirma- During a conference call held with Chel- *6 tory study support” to the new pivotal investors, Pedder, sea Dr. Simon Chelsea’s drug because of re- application, the failed Officer, President and Chief Executive de- Based on Study sults in 302. this addition- scribed December 2010 as a meeting recommendation, al Chelsea announced “successful outcome” that “reflected] trial, plans Study a new to initiate clinical strength by generated of the data” Chel- 306, involve eight-week which would an program, drug development sea’s and period. treatment significant step a for “mark[ed] forward Chelsea.” Dr. Pedder also stated that the 2010, Chelsea announced September “that concluded, officials had clarified additional had Study 301 and success- efficacy required” studies were not for a fully endpoint by revised had met its show- drug filing. new application On the same ing statistically significant improvеment a call, Sehwieterman, However, Dr. in conference William participants’ symptoms. 301, and Chief Medi- employed Chelsea’s Vice President Study which a treatment week, Officer, cal that after De- period only represented one of was the sole “very efficacy study meeting, conducted cember 2010 Chelsea was Chelsea endpoint. Study pleased” responses met FDA’s to primary its with the disease, study Study not 306 was later continued a re- but the results of would with focusing endpoint, prevention on the of vised be until 2012. available suffering patients from Parkinson's falls in application its site questions Chelsea’s about address where-the FDA briefing docu- and After these state- supporting data. ment later would be made available. concerning ments the December 2010 After the February press re- meeting, price Chelsea’s stock rose about issued, lease stock price Chelsea’s dropped percent. about percent. 37.5 When the briefing In September Chelsea announced document public eight days became later that it had to the FDA submitted its new February 21, on Chelsеa’s stock drug application purportedly on based “ro- price dropped an 21 percent. additional efficacy bust” data from Studies 301 and 23, 2012, On February however, However, as later observed FDA advisory committee announced its FDA, these involved treatment pe- studies non-binding recommendation favor of only of riods one week. approving Northera drug. as new Sev- In accordance with the FDA’s initial eral advisory members of the committee evaluation new process drug applica- raised the same concerns outlined in the tions, an FDA member prepared staff briefing staff Although document. the ad- briefing of document advance the meet- visory chairperson committee voted fa- ing of the FDA’s Cardiovascular Renal vor of approving drug, he nevertheless (the Drugs Advisory advisory Committee stated, “virtually all [members advi- committee), which held to was review sory agree that” the committee] failed application. briefing Chelsea’s docu- provide confirmatory studies “do not evi- ment included the staff member’s recom- dence of primary benefit. study, And Northera, against approval mendation [Study] 301[,] provide also did evidence which was based in part recommendation regarding the duration effect in on Chelsea’s failure demonstrate that way.” direct (i.e., had a “durable effect more 28, 2012, On March the FDA denied the weeks).” than 4 drug application. new The FDA provided February 13, eight days On before its “complete response decision in a let- the FDA briefing document was made ter,” stating, among things, other available to public, Chelsea issued a FDA required an additional successful release, press release. In the study support “durability of effect.” “receipt stated that it in brief- [the] document,” ing decision, and that “several lines of About a week after the FDA’s inquiry emerged ... the initial significant have in this case was filed. components analysis the benefit-risk later filed consolidated *7 (the Northera,” that including drug complaint), Chelsea’s class action complaint as- 10(b) development “may adequate- serting not program violations of Section of the ly 10b-5, Exchange establish durable treatment effect as Act and Rule SEC 10b-5). (Rule § a result of the short of’ the clini- C.F.R. In their duration 240.10b-5 however, complaint, cal trials. who Notably, plaintiffs, purchased Chelsea’s the press release did disclose that the Chelsea stock November not between (the FDA briefing period), document concluded with and March class including the Northera not asserted that recommendation that be claims numerous release, approved. the investors to Also that Chelsea defendants misled believe advisory approve stated that that the FDA Northera the committee would would only application February review the on based on the results of one successful Finally, efficacy study, though FDA the release included a web- even the re- of part that suc- scienter on the the defendants. had warned Chelsea two peatedly of of evidence “duration objected cessful studies and to plaintiffs The the court’s con- necessary for of approval would effect” be documents, assert- sideration of the SEC complaint, the drug. new In their the ing did not definitive- that the record show allegedly of identified dozens рlaintiffs ly any individual stock purchased “whether or material omis- misleading statements the during period” or sold class be- stock the sions defendants. any discovery cause had not been there a mo- response, the defendants filed the case. Rule complaint under tion to dismiss the At of the hearing, the conclusion 12(b)(6), contending judicial district took notice of the court made failed to show that defendants documents, granted and SEC the defen- materially statements or omis- any false to Applying dants’ motion dismiss. sions, any and such statements or Pri- heightened pleading standards of the the required were made with omissions not Litigation Act vate Securities Reform their scienter. The defendants attached to (PSLRA), 78u-4(b)(2), U.S.C. motion several asked the exhibits judicial court to take notice of them. court held securities fraud claims failed because the exhibits to this in- appeal The relevant sup- did not plead sufficient clude three documents that were filed with of port strong inference scienter. (collectively, the the SEC SEC docu- ments). Two of these documents are SEC The court that al- district concluded reports, by Dr. “Form 4” filed Schwieter- though defendants’ statements to in- Person,” the “Reporting showing man as during period “may the class vestors have corporate employed that while as a officer overly optimistic been about the [likelihood purchases he made two stock Chelsea Northera,” approving the] those during period. the class statements did demonstrate The third document submitted of scienter reasons. inference two defendants, a Proxy “Definitive State- First, the court observed that the defen- SEC, ment” that filed with the provided many warnings dants to investors listed the amount stock of Chelsea shares sufficiency regarding of the new by the company’s held officers the end Second, application. the court found that February the end of near the class when weighing competing inferences period. Proxy Statement showed scienter, “the in- regarding glaring” most percent Dr. Pedder owned 2.8 all shares that none ference “the fact stock, other of Chelsea while officers during individual defendants sold stock owned lesser amounts of Chelsea stock. ’ (Emphasis class period.” original). However, the Proxy Statement did not lack of stock court concluded reflect whether these stock holdings sales the scales in favor of defen- acquired during “tip[ped] had been or sold the class period. dismiss, rendering dants’] motion” plaintiffs’ allegations insufficient as a mat- dismiss, hearing
At a on the motion to *8 ter of infer- required law to establish the represented the defendants none of ence of After the district court scienter. any the Chelsea officers had sold shares with dismissing entered its order the case during period. Chelsea stock the class prejudice, plaintiffs timely filed The argued defendants absence of any appeal. such sales undermined inference of
II. We also review principles addressing the required scienter for such claims. In addressing plaintiffs’ arguments, applicable we first state the standard of Exchange Act and related review. consider de novo the district We regulations ensure that public companies plaintiffs’ complaint court’s dismissal of the release information that permit will “in 'under Federal Rule of Civil Procеdure vestors to make informed investment deci 12(b)(6). Cozart, Wag Dogs, More LLC v. (4th sions.” Yates v. Mun. Cir.2012). Mortg. Equity, & 680 F.3d
LLC, (4th Cir.2014) (cit 744 F.3d A. ing Taylor S.C., Corp. v. First Union Cir.1988)). argue first that the district Under 10(b) by court erred considering Act, the SEC docu- Section of the companies are ments by submitted the defendants that prohibited using “any from manipulative integral complaint, were not to the and or deceptive device or contrivance” in con concluding based on those documents that nection security with the sale of a in viola none of the individual defendants sold § tion of 78j(b). SEC rules. See 15 U.S.C. Chelsea stock during period. the class Ac- Pursuant to regulatory proscription in cording plaintiffs, the district court’s' 10b-5, Rule the following conduct is un improper consideration and incorrect in- lawful in connection with sale of a se terpretation of these documents contribut- curity: ed to the court’s erroneous conclusion To make untrue statement of a ma- plead defendants failed to sufficient terial fact or to omit to state a material supporting facts inference of fact necessary order to make the scienter. made, light statements in the of the response, the defendants contend they circumstances under which were that the district court properly considered made, misleading...'. the SEC documents submitted with their motion to Arguing dismiss. that courts 240.10b-5(b). 17 C.F.R. “routinely filings examine” SEC Generally, plaintiff asserting a
pleading stage of
litiga-
securities fraud
10(b)
claim under Section
must establish:
tion, the defendants assert that the district
“(1)
misrepresentation
a material
or omis
taking judicial
court did not err in
notice of
(3)
defendant; (2) scienter;
sion
contents
the two Form 4 exhibits
misrepresentation
connection between the
and
Proxy
Statement exhibit. The
purchase
or omission and the
or sale of a
defendants
submit
these documents
(4)
security;
reliance upon
misrepre
supported the district
findings
court’s
omission; (5)
loss;
sentation or
economic
the individual defendants failed to sell
(6)
Yates,
loss causation.”
744 F.3d at
stock,
shares of Chelsea
and did not know-
(citation omitted);
see Matrixx Initia
ingly
recklessly
misleading
make
state-
, —
tives,
-,
Inc. v.
U.S.
ments.
disagree
We
with the defendants’
Siracusano
1309, 1322,
131 S.Ct.
To demonstrate compelling opposing the defendant acted is at least as tiff must show Zucco embracing (quoting intent to inference.” Id. state innocent “a mental with Tellabs, Partners, 552 deceive, Digimarx Corp., defraud.” LLC manipulate, or v. (citation (9th Cir.2009)). 981, 2499 In evaluat at 127 S.Ct. 991 551 U.S. F.3d omitted). inferences, of reckless conduct the scien Allegations ing these we consider necessary of scienter satisfy holistically can the level and accord those allegations ter to dismiss. See Ma weight a motion warrant allegations to survive “the inferential F.3d at Reckless Capital, trix 576 by context and common sense.” Ma ed in strong establish a sufficient to (citing conduct at Cozza Capital, 576 F.3d 183 trix 625-26). is described as “se relli, ference of scienter 549 F.3d at vere,” Orthopedic Hanger v. Ottmann (4th Inc., Cir.2003),
Grр.,
353 F.3d
highly
that is “so
unreasonable
or conduct
In view of these
principles,
departure from the
an extreme
and such
turn
address the
claims
n
ordinary
present
care as to
standard of
anal
the district court erred
its scienter
misleading
plaintiff
to the
danger of
documents
ysis by considering the SEC
n
danger
was either known
extent
that were not
by
submitted
the defendants
or so obvious
to the defendant
Generally,
integral
complaint.
when
of it.”
must have been aware
defendant
complaint
moves to dismiss a
defendant
(citation
at 181
Capital,
Matrix
F.3d
12(b)(6),
Rule
courts are limited to
under
omitted).
quotation
and internal
marks
considering
sufficiency
allegations
complaint
forth in the
and the “docu
set
are
Claims of securities fraud
into the
incorporated
attached or
ments
pleading standard
subject
heightened
to a
E.I. du Pont de Nemours &
complaint.”
Yates,
period, any or other basis de- termining whether officers other corporate plaintiffs The that in addi argue Dr. Schwieterman or sold purchased than district in relying tion to the court’s error any during of their that Chelsea stock documents, challenged on the SEC period. erred in concluding court further that their
Instead, of scienter were insufficient as only the Form 4 list documents asserting they a matter of law. In that “Reporting Dr. Schwieterman Per- as the son,” pleaded strong not facts a inference any permitting and do contain reference scienter, any corporate plaintiffs rely other on their alle officer. And Proxy provides only “snapshot intentionally statement a that gations defendants recklessly time” stock shares owned failed to disclose February various Chelsea as of expected produce officers Chelsea to two suc Therefore, regardless whether the studies showing cessful evidence of dura information contained in the SEC docu- bility plaintiffs The place partic of effect. judi- ments could be under the considered emphasis ular on their that the allegation provisions cial notice such of Rule intentionally defendants misled investors not provide information did a factual basis release, February in the press for the court’s conclusion no individual failing briefing to disclose that the FDA during sold defendant Chelsea stock included document a recommendation Clatterbuck, See period. class against approval plain Northera. 557-58. tiffs assert the defendants because were aware of this adverse recommenda also disagree We with the defen it, supports tion but withheld such conduct argument dants’ if the district even strong wrongful inference intent. in this regard, court erred the court’s con response, did not In maintain sideration SEC documents defendants the outcome allege affect of the court’s decision that the failed to sufficient concerning support adequacy strong facts inference of allegations. weighing competing scienter. defendants submit be- inferences, they court concluded disclosed various district cause to investors purported failure to of their drug application, defendants’ weaknesses new period stock the class during sell Chelsea the defendants’ omission of other informa- support tion does not inference of mission of the drug application new based respect February only scienter. With Study on the defendants instead release, press the defendants ar- informed investors that the FDA had gue that their omission of “agreed” the adverse that Chelsea could submit its new FDA staff recommendation does dem- application for Northera “without the intent, wrongful onstrate because need for further efficacy studies.” press However, release included a website address even assuming that this state- eight days where investors later could lo- truthfully ment represented an FDA com- cate the full FDA briefing document. We munication that Chelsea’s new drug appli- disagree position. with the defendants’ submitted, cation could be the statement *12 was misleading given the FDA’s continu- Supreme As the emphasized Court ing expеctation that two efficacy successful Initiatives, Matrixx “companies can con- studies would be required for approval of trol they what have to disclose under [Sec- Northera. 10(b) 10b-5(b) tion by and Rule ] control- ling they say what to the market.” 131 The defendants also were by aware De- Thus, S.Ct. at 1322. while Chelsea and its cember 2010 that the lone successful effi- corporate may officers trial, have lacked an in- cacy Study involved a treatment dependent, duty affirmative period week, to disclose the only one in contrast to the FDA adverse staff recommendation and failed Study 303 and the Study abandoned shortcomings the Chelsea’s evidence of which both involved longer much efficacy, the defendants’ failure to do so periods. Nonetheless, treatment the de- 10(b) must be viewed under Section and fendants described their December 2010 10b-5(b) Rule in the context of meeting the state- with the FDA as a “successful that they affirmatively ments elected to reflecting outcome” the “strength of the make. See id. data” gathered during the clinical trials. review,
Based on our de novo wе con- durability The issue of of effect is a core clude plaintiffs’ that the complaint, component when plaintiffs’ allegations, entirety, viewed its along contains sufficient expectation with the FDA’s of two allegations giving rise to a strong infer- Critically, successful studies. the plaintiffs of scienter. This strong ence inference of alleged that Chelsea that knew the FDA intentional or reckless conduct sup- expected effect, is durability evidence of ported by plaintiffs’ the just not efficacy, evidence of and that material, non-public information known to “Chelsea was aware of Study 301 and the defendants about the status of the new Study 302’s durational-benefit shortcom- ¶ drug application required efficacy ings.” JA 65 106. studies conflicted with the defendants’ Although the FDA approve a new .can
public subjects. statements on those drug on only based results of one success-
According
allegations,
study,
study
ful
“adequate”
must be
although the defendants knew that
present
and the data must
“substantial
FDA expected
efficacy
two successful
evidence that the
will
have
effect
355(d).
demonstrating durability
studies
purports.”
of effect
it
See U.S.C.
Ad-
to support regulatory approval of North-
ditionally,
plaintiffs
allege
did not
era, none of the defendants’ statements
unreasonably sought
to Chelsea
review
investors
expecta-
addressed this critical
FDA
on the basis of one successful
tion. After the
study.
defendants met with FDA
plaintiffs
alleged
instead
officials December 2010 to discuss sub-
regarding
misled investors
defendants
imprecise
the new
an
medical term when describ-
submitting
drug appli-
the risk of
by a
one-
only
single,
cation supported
ing
study, alleg-
of a clinical
endpoint
scant
study providing
week
evidence
edly with
mislead
the intent to
investors
durability of effect.
likely to
study
think that
succeed.
549 F.3d at
We
624-26.
concluded
significant
also made a
only
not
term
general
was the
used
fail-
allegation concerning
defendants’
corporate officer “more
less inter-
February
ure
in the
to disclose
changeable”
precise
with the
term not ref-
press
briefing
that the
docu-
release
erenced,
against
ment
a recommendation
pharmaceutical
contained
but that the
com-
In
re-
approval
press
of Northera.
its
pany also
investors that it
informed
would
lease,
stated that
Chelsea instead
not
of the study
disclose the details
briefing
had
document and
received
at 626.
“competitive reasons.” Id.
There-
lines
inquiry”
disclosed that “several
fore, we
in Cozzarelli
concluded
including
efficacy
had
emerged,
corporate
language
officer’s chosen
did not
“may
adequately
trials
establish
du-
support
inference of scienter.7
rable
effect.”6
omis-
treatment
Chelsea’s
Id.
627-28.
regarding
sion of the information
the ad-
contrast,
present
case involves
recommendation,
verse FDA staff
when
*13
misleading
numerous allegedly
statements
prob-
in the context of the known
viewed
by
and omissions
the defendants that were
efficacy
lems
studies
of the
and Chelsea’s
by
imprecise
the use of
studies,
caused
lan-
regarding
earlier remarks
those
guage
a
supports
legitimate
the inference
Chelsea inten-
the execution of
busi-
recklessly
Instead,
tionally or
misled investors.
ness
the
decision.
alle-
gations,
in the
when considered
context of
allegations
are
significantly
These
the entire
a
complaint, permit
strong infer-
stronger
allegations
than the
consid-
we
knowingly
ence
the defendants either
Cozzarelli,
ered in
a case on
the
which
by
or recklessly
failing
misled investors
to
Cozzarelli,
rely. In
defendants
which also
disclose critical information
from
received
pharmaceutical
a
at-
company’s
involved
FDA during
the new
application
tempt
gain
approval
drug,
a
to
process,
releasing
less
in-
plaintiffs’ primary allegation
damaging
while
of scien-
ter
corporate
they
focused on a
officer’s use of
formation that
knew was incomplete.8
assertion,
Contrary
give
strong
to the dissent's
sions themselves
rise to a
infer-
prices
change
scienter,
in Chelsea stock
after Chelsea's
ence of
we need not
consider
relevant to the
statements is
element of mate-
plaintiffs'
allegations regarding
additional
impact
riality,
our
and does not
consideration
defendants’ financial motivations.
allegations
of scienter.
dissenting opinion
8.The
states
Dr. Ped-
concluding
plaintiffs' аllega-
After
acknowledged
der
one of the
to
obstacles
failed to
tions in
show scienter
Cozzarelli
drug approval by stating, after the December
allegedly
based on the
intentional false state-
meeting,
2010
that the FDA was interested
officer,
corporate
by
proceeded
ment
we
"
seeing
"in
'two additional studies.’ Howev-
plaintiffs'
other
consider the
er, Dr.
did not
Pedder’s statement
acknowl-
scienter,
the company’s
which involved
finan-
edge
expected to see
that the FDA
two suc-
cial
motivations and
sales of stock
showing durability
cessful studies
of effect.
corporate officers.
611 emphasize that our We conclusion does tiffs’ on the basis that allega- that a proposition strong not stand for tions supporting an inference of scienter merely inference of scienter can arise were legally judgment and remand the on a defendant’s failure to based disclose case for further proceedings. Rather, inquiry
information. the scienter VACATEDAND REMANDED. necessarily involves consideration of the alleged facts and of nature of the misleading omissions or statements within THACKER, Judge, Circuit dissenting:
the context of the statements that a defen-
PSLRA,
Since the enactment of the
we
dant affirmatively made.9 See Matrixx
published eight
have
decisions reviewing
Initiatives,
(stating
larity giving strong facts rise to a infer- III. ence that the defendant acted with the reasons, required § For these state of mind.” we hold that 15 U.S.C. 78u- 4(b)(2)(A). district court erred in dismissing plain- strong To еstablish this infer- appears rely the dissent plead allegations demonstrating to on the defendants’ in- 28, 2012, statements made conclusions, on March after the ference of scienter. Such how- application. denied the new ever, necessarily fact-dependent are and do however, point, defendants’ statements at that compel present a result in the case. plaintiffs’ allegations are not relevant to the scienter. 10. We do not address the derivative claims, 20(a) Section which also should be dissenting opinion, 9. As observed in the this many plain- Court times has considered on remand. concluded that a asserting tiff securities fraud claims failed to 612 recklessness,’ recklessness,’ ‘severe the court scious persuade ence, must plaintiff ” Ann recklessness.’ high degree ‘a that the defendant likely as not it is as Olazábal, or, very Defining Recklessness: at the intent Morales with fraudulent
acted
Deterrence
least,
Approach
severe recklessness
to
“such
A Doctrinal
with
Fraud,
investors was
misleading
2010
danger of
Securities
Secondary
Market
omitted)
(footnotes
or so obvi-
to the defendant
1415,
either known
1424
L.Rev.
Wis.
have been
must
the defendant
cases).
ous
(collecting
Pharm.
Inspire
v.
it.” Cozzarelli
aware of
circuit,
allega
recognize
this
(in-
(4th Cir.2008)
618,
Inc.,
F.3d
623
satisfy
can
the scien
tions of recklessness
omitted). Here,
marks
quotation
ternal
Capital
see Matrix
requirement,
ter
strongly imply either
do not
Inc.,
Fund,
BearingPoint,
LP v.
Mgmt.
or severe recklessness.
intent
fraudulent
(4th Cir.2009);
172,
see also
576 F.3d
that Chel-
Instead,
allegations suggest
Inc.,
Orthopedic Grp.,
Hanger
v.
Ottmann
the various
acknowledging
sea—while
(4th Cir.2003)
(recogniz
353 F.3d
encumbering its
and setbacks
challenges
circuit that “a
first time
ing for the
approval
for FDA
bid
—submitted
plaintiff may allege scien
securities fraud
justifiable confi-
application with
Northera
only intentional mis
by pleading not
ter
I
for success.
there-
in its chances
dence
recklessness”),
conduct,
but we
but also
dissent.1
respectfully
fore
“se
that the recklessness must be
insist
is,
species
I.
lesser
slightly
“a
vere”—that
misconduct.”, Ottmann, 353
intentional
A.
(internal quotation marks
F.3d at 344
Scienter,
Supreme
as defined
Cozzarelli,
omitted);
549 F.3d
see also
Court,
embracing intent
“a mental state
is
Hunter,
623;
Sys. La. v.
Tеachers’ Ret.
deceive,
Ernst
manipulate, or defraud.”
Cir.2007).
This
n.
Hochfelder,
425 U.S.
& Ernst
recklessness,
stated,
we have
definition of
(1976).
613
Cir.2009) (“In
in
form of
order
scienter —whether
to establish a
pleading
scienter,
intent or severe recklessness—
of
plaintiffs
fraudulent
inference
must
intent.”
showing
“wrongful
a
requires
merely
do more than
demonstrate
There,
group
at 621.
a
share-
defendants
should or could
done
have
alleged
drugmaker seeking
that a
holders
They
more.
must
[de-
demonstrate that
eye-dis-
an experimental
approval
complicit
either knowingly
fendants] were
into
misled investors
be-
ease treatment
fraud,
or so
reckless
their duties
trial
lieving
important
that an
clinical
was
as to be oblivious to malfeasance that was
likely
succeed. See id. at 624-25. The
to
readily
understanding
apparent.”). This
allegedly
this false
drugmaker
nurtured
it necessarily
scienter —that
a “cul-
entails
impression
withholding details about
mind,” Ottmann,
pablе state of
F.3d at
353
endpoint
simultaneously
while
the trial’s
10(b)
preserves section
a prohibi-
as
348—
“very
that the trial
simi-
representing
tion on securities
It
ensures
fraud.
previous
Id. at
lar” to
successful trial.
corporations and their officers cannot es-
(internal
omitted).
quotation
625
marks
liability
cape
through willful blindness—
allegations sup-
concluded that
We
is,
ignorance
truth
purposeful
ported
drugmaker
an inference that
representations while,
of their
at
own
—
only
protect
to
its
ad-
sought
competitive
10(b)
time,
prevents
it
same
section
from
inference,
in marketplace;
vantage
devolving
penalty
into
deci-
business
stated,
powerful
compel-
“is more
that,
hindsight, appear
sions
questiona-
drugmak-
ling than the inference that [the
ble.
with an intent to
Id. at
acted
deceive.”
er]
supplied).
(emphasis
626
B.
years
In the
since
our court
Cozzarelli
occasionally
neglected
has
to note
Here,
heightened
under
PSLRA’s
necessary
support
recklessness
find
standard,
re
pleading
were
ing
must be
Com
of scienter
“severe.”
quired
allege
to a
giving
facts
rise
LLC,
v. Mun.
pare
Mortg. Equity,
Yates
&
or
strong inference of fraudulent
intent
(“At
(4th Cir.2014)
744
F.3d
884
78u-
severe recklessness. See U.S.C.
stage, alleging
intentional
pleading
either
4(b)(2)(A);
II. Hernandez, ful, De- Jonathan a/k/a fendant-Appellant. we do not As we stated Cozzarelli 13-4630, 13-4644, 13-4877. every bullish state- Nos. “from infer scienter company that pharmaceutical ment Appeals, Court of United States 618, F.3d funds.” 549 trying to raise Fourth Circuit. Cir.2008). did, “we would If we of innovation off the lifeblood choke Jan. Argued: litigation.” frivolous by fueling medicine March Decided: way Today’s decision clears Id. the risk that litigation, heightening
more judicial pro- exploit will
shareholders corpora- from to extract settlements
cess exactly This is they chose to fund.
tions it prevent when Congress sought
what Tellabs, Inc. v. the PSLRA. See
enacted Ltd., 551 U.S. Rights, Issues &
Makor L.Ed.2d 179 S.Ct.
(2007). I would affirm the Accordingly, the district court.
judgment of America, STATES
UNITED
Plaintiff-Appellee,
v. CORNELL, King
Jorge Peter a/k/a King Jay,
J, Defendant- a/k/a
Appellant. America,
United States
Plaintiff-Appellee, Yayo, Wilson, King
Ernesto a/k/a
Defendant-Appellant.